Company news

Ascletis Pharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Next Day Disclosure Return

October 29, 2026

Voluntary announcement - ascletis' oral small molecule glp-1, ASC30, demonstrated placebo-adjusted HBA1C reduction of 1.7% at 12 weeks from its U.S. phase ii study in participants with diabetes

October 28, 2026

Next Day Disclosure Return

October 27, 2026

Next Day Disclosure Return

October 26, 2026

Voluntary announcement - ascletis announces FDA ind submission of ASC39, an oral small molecule selective amylin receptor agonist for the treatment of obesity

October 25, 2026

Next Day Disclosure Return

October 23, 2026

Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acne

October 22, 2026

Next Day Disclosure Return

October 22, 2026

Next Day Disclosure Return

October 21, 2026

Next Day Disclosure Return

October 20, 2026

Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity

October 19, 2026

Next Day Disclosure Return

October 16, 2026

Next Day Disclosure Return

October 15, 2026

Next Day Disclosure Return

October 14, 2026

Next Day Disclosure Return

October 13, 2026

Next Day Disclosure Return

October 12, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 6, 2026

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

October 2, 2026

Voluntary announcement - ascletis' ASC36_35FDC demonstrated potential for once-monthly to once-quarterly dosing and robust weight-loss in preclinical studies presented at EASD 2026

October 2, 2026

Interim Report 2026

September 29, 2026

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

September 28, 2026

Voluntary announcement - ascletis announces positive results from 28-day proof-of-concept clinical study in U.S. for ASC50, a first-in-class and best-in-class oral small molecule IL-17A inhibitor for the treatment of plaque psoriasis

September 28, 2026

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

September 8, 2026

Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

September 7, 2026

Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management

August 30, 2026

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35

August 10, 2026

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

August 3, 2026

Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model

July 27, 2026

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting

July 22, 2026

Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30

July 15, 2026

Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

July 5, 2026

Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

July 5, 2026

Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

June 23, 2026

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39

June 7, 2026

Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)

May 5, 2026

Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions

April 29, 2026

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

April 26, 2026

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

April 7, 2026

Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity

March 10, 2026

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

February 10, 2026

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

January 29, 2026

Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes

January 25, 2026

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

January 20, 2026

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

January 4, 2026

Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

December 15, 2025

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

December 10, 2025

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

December 8, 2025

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

November 30, 2025

ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight

November 13, 2025

Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development

November 12, 2025

Older news releases →

Decks